The emergency use listing is based on non-clinical data where the vaccine demonstrated immune responses against variants in ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Erin Kissane, a co-founder of the COVID Tracking Project, rolled up her sleeve for the Novavax COVID-19 vaccine in ...

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, announced the European Commission has granted approval for Nuvaxovid XBB.1.5 dispersion for injection Covid ...

Novavax's updated COVID-19 vaccine is the only updated protein-based non-mRNA COVID-19 vaccine available in the European Union for individuals aged 12 and older Novavax is working closely with EU ...

The single-target vaccine is aimed at the XBB.1.5 Omicron subvariant of the coronavirus, which was dominant in the U.S. for ...

The U.S Food and Drug Administration approved the first chikungunya vaccine- Ixchiq Ixchiq is administered as a single dose intra-muscularly for individuals over 18 years of age and older who are ...

A: The CDC has authorized two RSV vaccines for the prevention of lower respiratory tract disease in people 60 and older. The ...

Novavax announced that Nuvaxovid XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the ...